NCT00480701View on ClinicalTrials.gov

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Alzheimer DiseaseParkinson Disease
Interventions
DRUG

[123I]-IBVM

Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.

Trial Locations (1)

06510

Institute for Neurodegenerative Disorders, New Haven

All Listed Sponsors
lead

Institute for Neurodegenerative Disorders

OTHER

NCT00480701 - Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease | Biotech Hunter | Biotech Hunter